Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

- (Currently Amended) A method of treating—reducing a lesson of cerebral tissue
 induced by cerebral ischemia, wherein the cerebral ischemia occurs as a result of apoplexy,
 sakh method comprising the step of administering to a subject in need thereof a medicament
 comprising a neuroprotective amount of an active ingredient comprising a hydrogenation product
 of Boswellia serrata obtained through the catalytic hydrogenation of ethanol extracts of
 frankincense (Boswellia serrata).
- 2. (Canceled) The method according to claim 1, wherein the cerebral is chemic occurrence result of anothers.
- (Previously Presented) The method according to claim 1, wherein the active ingredient comprises frankincense or a boswellic acid-containing vegetable extract.
- 4. (Previously Presented) The method according to claim 1, wherein the frankincense extract is selected from the group consisting of a keto-boswellic acid, 3-O-acetyl-11-keto-β-boswellic acid, 11-keto-β-boswellic acid, a physiologically acceptable salt of a keto-boswellic acid, a derivative of a keto-boswellic acid, a salt of a keto-boswellic acid derivative, and a keto-boswellic acid-containing vegetable extract.

Serial No.: 10/549.323 Attv. Docket No.: LNK-007

Response of May 21, 2009

5. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises a tirucallic acid, another triterpene or a salt or derivative thereof or a vegetable extract containing a tirucallic acid, another triterpene or a salt or derivative thereof.

(Previously Presented) The method according to claim 1, wherein the frankincense 6. extract comprises an extract from a Boswellia serrata resin.

7. (Currently Amended) A method of reducing a lesion of cerebral tissue induced by treating a cranial/brain trauma or, a short-term cerebral ischemia resulting from apoptex; or cardiac infarction, said method and/or-Alzheimer's disease comprising the step of administering to a subject in need thereof a medicament comprising a neuroprotective amount of an active ingredient selected from the group consisting of: a hydrogenation product of a frankincense extract and a physiologically acceptable salt of said hydrogenation product.

(Canceled) "The method according to claim 7, wherein the medicament is used for treating-Alzheimer's disease.

9. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenation product of a boswellic acid-containing vegetable extract.

10 (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenated product of a frankincense extract obtained from a Boswellia serrata resin.

-3-

Serial No.: 10/549,323 Attv. Docket No.: LNK-007

Response of May 21, 2009

11. (Previously Presented) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a hydrogenation product of boswellic acid and a

physiologically acceptable salt of said hydrogenation product.

12. (Canceled).

13. (Canceled)

(Canceled)

15. (Previously Presented) The method according to claim 7, wherein the active ingredient is

selected from the group consisting of a hydrogenation product of tirucallic acid and a

physiologically acceptable salt of said hydrogenation product.

 (Previously Presented) The method according to claim 1, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous,

intraarticular, intravenous, intrathecal or intracranial administration.

17. (Previously Presented) The method according to claim 1, wherein the medicament

comprises a tablet or solution.

18. (Previously Presented) The method according to claim 7, wherein the medicament is

formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous,

intraarticular, intravenous, intrathecal or intracranial administration.

19. (Previously Presented) The method according to claim 7, wherein the medicament

comprises a tablet or solution.

-4-